Dizal : ZEGFROVY Meets Primary Endpoint In Phase 3 NSCLC Study

Dizal's multinational Phase 3 WU-KONG28 study of ZEGFROVY (sunvozertinib) monotherapy in first-line NSCLC patients with EGFR exon 20 insertion mutations met its primary endpoint. This positive Phase 3 result materially de-risks the program and supports potential regulatory filings and commercial opportunity in a hard-to-treat exon20ins population. Expect upward pressure on Dizal shares and heightened investor focus while waiting for full data release and regulatory plans.

Analysis

Dizal's multinational Phase 3 WU-KONG28 study of ZEGFROVY (sunvozertinib) monotherapy in first-line NSCLC patients with EGFR exon 20 insertion mutations met its primary endpoint. This positive Phase 3 result materially de-risks the program and supports potential regulatory filings and commercial opportunity in a hard-to-treat exon20ins population. Expect upward pressure on Dizal shares and heightened investor focus while waiting for full data release and regulatory plans.